Abstract
Canine babesiosis is an important worldwide, tick-borne disease caused by hemoprotozoan parasites of the genus Babesia. Babesia gibsoni is the predominant species that causes canine babesiosis in Taipei, Taiwan. It is a small pleomorphic intraerythrocytic parasite that can cause erythrocyte destruction and hemolytic anemia. Efficacy of oral administration of a doxycycline-enrofloxacin-metronidazole combination with and without injections of diminazene diaceturate in the management of naturally occurring canine babesiosis caused by B. gibsoni was evaluated retrospectively. The overall efficacy of this combination of doxycycline-enrofloxacin-metronidazole in conjunction with and without administration of diminazene diaceturate was 85.7% and 83.3%, respectively; with a mean recovery time of 24.2 and 23.5 days, respectively. Concomitant use of intramuscular diminazene diaceturate may not improve the efficacy of a doxycycline-enrofloxacin-metronidazole combination in management of canine babesiosis caused by B. gibsoni.
Highlights
Canine babesiosis is an important worldwide, tick-borne disease caused by hemoprotozoan parasites of the genus Babesia, and the predominant species infecting dogs is B. vogeli [1]
The aim of this study was to evaluate the efficacy of a doxycycline-enrofloxacin-metronidazole (DE-M) combination with and without administration of diminazene diaceturate to manage naturally occurring canine babesiosis caused by B. gibsoni
Results of the Cox proportional hazard model indicated that relapse of anemia and persistent parasitemia was not associated with sex, age or severity of anemia at diagno
Summary
Canine babesiosis is an important worldwide, tick-borne disease caused by hemoprotozoan parasites of the genus Babesia. B. gibsoni was found to be the major causative agent of canine babesiosis in Taipei, Taiwan [2]. Efficacy of diminazene diaceturate in management of canine babesiosis is limited, but this is the only diminazene available for veterinary use in Taiwan, whereas atovaquone is not yet available.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
